Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > CR going up!!!
View:
Post by Oilminerdeluxe on Feb 01, 2021 7:21am

CR going up!!!

Unless I read it wrong, 44% CR at 180 days + 2 patients left to be determined. Only 1 with no response at all. If one or both of them gets a CR, well, we should feel in a beter mood, right...??

This HAS to be good
Comment by fredgoodwinson on Feb 01, 2021 7:38am
Is it correct that the 9 patients are arrived at by taking 5 withdrawn from the original 12 to leave 7 and then adding Patients 13 & 14? If so the 2 'to be determined' will be the only ones to have received the correct full dosing so might await their outcomes with some optimism.
Comment by Eoganacht on Feb 01, 2021 10:42am
That's what it looks like. The 45% CR would be the percentage of CR patients from the 9 patients who have received or will receive a 180 day assessment. If 13 and 14 are CR then we'll be at 67% CR of those patients. Things look really great going forward.
Comment by Rumpl3StiltSkin on Feb 01, 2021 11:14am
I'm guessing TLT will get another 10 enrolled in study 2 in Canada this qtr. By Summer another 10 in Canada and perhaps 25 in the US? So I think the CR % by fall 2022 will be 80% + as these patients approach their 15 month CR dates. :-)
Comment by Macer on Feb 01, 2021 7:50am
  I am totally confident that the treatment works, if it is delivered properly. The CR numbers don't mean much right now. The catalyst that we need is enrollment. Doesn't sound like they are getting priority placements for OR time. GBM and NSLC in 2022? Why do they always put these dates out when they have no clue when this will begin. At least the days are getting longer now.  ...more  
Comment by Oilminerdeluxe on Feb 01, 2021 7:56am
At least it wasn't a sucky newsletter this time around. :-) Happy to see they will contonue with viruses and Dr. Combs. But iI suspect that to be a slow process as well. Here's to American hopsitals enrolling patients asap
Comment by fredgoodwinson on Feb 01, 2021 7:56am
Apologies - others have received the optimised dose  - this was the position before 13 & 14:   ‘2 out of the last 5 patients treated for the second time have been treated with the optimized Study II treatment, which will also be the case for the 2 patients that are pending their second treatment.’   but 13 & 14 will - uniquely to date - have received the optimised ...more  
Comment by enriquesuave on Feb 01, 2021 8:37am
From memory, I believe only 4 of the first set of 12 have received a second treatment which was optimized.  At 180 days we have 4 CR and 2 pending.  The only 2 pending at day 180 are patients 13 &14 IMO.  They also got optimized treatments.  Looking amazing.  What this shows is that the treatment works when given properly  Maximum Bladder Volume used.  If ...more  
Comment by Macer on Feb 01, 2021 8:52am
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250